First Combination Off The Shelf NK And Adaptive Immunotherapy Trial To Be Initiated For Pancreatic, Lung, Breast, Colon, Melanoma, Sarcoma, Chordoma, Head And Neck, Non Hodgkin’s Lymphoma, Merkel Cell And Ovarian Cancers.
First Whole Genome, Transcriptomic, Proteomic (GPS Cancer) Informed Immunotherapy Trials Across All Tumor Types
The NANT Cancer Vaccine program is a personalized, molecularly-informed therapy guided by NantHealth’s GPS Cancer test that includes the simultaneous combination of off the shelf natural killer cells (NK) with the endogenous activation of dendritic, T cell and NK cells to more fully enhance the innate and adaptive immune system of cancer patients.
The NANT Cancer Vaccine is the first combination immunotherapy protocol formulated to include the novel delivery of metronomic, low-dose chemotherapy and radiation with molecularly-informed, tumor-associated antigen vaccines, together with NantKwest’s NK cell therapy, to induce immunogenic cell death while avoiding the ravages of toxic high dose chemotherapy.
By inducing immunogenic cell death and enhancing a patient’s innate and adaptive immune system, the NANT Cancer Vaccine is designed to attain a long-term, durable response in multiple cancer types with lower toxicity and higher efficacy in comparison with current standards of care.
“Current therapeutic approaches to the treatment of cancer are often
inadequate to fully activate a patient’s immune response. Through the
NANT Cancer Vaccine program, we believe we can help facilitate a
paradigm shift in cancer care with the first clinical program formulated
to incorporate low dose, metronomic chemotherapy and radiation, combined
with molecularly-informed tumor associated antigens that are designed to
activate dendritic and T cells by adenoviral and yeast vaccine vectors,
together with both endogenous (IL-15) and exogenous (off the shelf)
activation of NantKwest’s NK cell therapy,” said
Dr. Soon-Shiong continued, “In addition to the previously announced
Pancreatic Cancer Vaccine, we are now actively working to initiate
multiple clinical trials across a wide range of cancer types which
include: Lung, breast, head and neck cancer, colon, melanoma, ovarian,
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, among others, statements concerning
or implying the timing and conduct of our clinical studies, the
anticipated safety and efficacy of our NK cell therapy and the
accomplishment and timing of related regulatory determinations and
filings. Forward-looking statements are based on management’s current
expectations and are subject to various risks and uncertainties that
could cause actual results to differ materially and adversely from those
expressed or implied by such forward-looking statements. Accordingly,
these forward-looking statements do not constitute guarantees of future
performance, and you are cautioned not to place undue reliance on these
forward-looking statements. Risks and uncertainties include, but are not
limited to, the rate of subject enrollment in our clinical studies; the
number of subjects that will need to be enrolled in the trial;
difficulty obtaining and maintaining regulatory approvals; our limited
experience in conducting clinical studies and significant issues
regarding our clinical studies, including, but not limited to, the
successful opening and the continued participation of clinical sites and
their ongoing adherence to protocols, assumptions regarding enrollment
rates, timing and availability of subjects meeting inclusion and
exclusion criteria, changes to protocols or regulatory requirements, the
ability to comply with and meet applicable laws and regulations,
unexpected adverse events or safety issues and the sufficiency of
funding and adverse events effecting our ability to manufacture and
supply cell therapy for our clinical studies. There can be no assurance
that data from any of our clinical studies will be sufficient to support
an application for marketing in any country or that any such application
will ever be approved. These and other risks regarding our business are
described in detail in our
About NANT Cancer Vaccine
The NANT Cancer Vaccine is the first combination immunotherapy protocol to orchestrate the delivery of metronomic low dose radiation and chemotherapy with molecularly informed tumor associated antigen vaccines and natural killer cells, to activate the innate and adaptive immune system and to induce immunogenic cell death. By inducing immunogenic cell death and protecting as well as enhancing the innate and adaptive immune system, the NANT Cancer Vaccine seeks to attain long-term sustainable remission of multiple tumor types with lower toxicity and higher efficacy than current standards of care.
NantKwest’s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and (3) Targeted activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of T cell therapies including the reduction of risk of serious “cytokine storms” reported after T cell therapy. As an “off-the-shelf” therapy, NantKwest’s NK cells do not rely on a patient’s own often compromised immune system. In Phase 1 clinical trials in patients with late stage cancer, NantKwest’s NK cells have been successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion cells.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe
About GPS Cancer
GPS Cancer™ is a comprehensive molecular profile available through
Founded by Dr.